Rufinamide

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 647-655

  Biton, Victor ^a  

^a Arkansas Epilepsy Program   (United States)

Author keywords

Efficacy studies of rufinamide in epilepsy; Impaired renal function; Lennox Gastaut syndrome multicentre, double blind parallel group design; Monotherapy studies in patients with partial onset seizures; Pharmacokinetics absorption and bioavailability; Population pharmacokinetic modelling; Rufinamide

Indexed keywords

EID: 77953196486     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch51     Document Type: Chapter

References (41)

1. Arroyo, S. Rufinamide. Neurotherapeutics 2007; 4: 155-162.
2. Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Prac 2006; 60: 1497-1501.
3. Biton V. Rufinamide. In: Shorvon S, Perucca E, Fish D, Dodson E (eds). The Treatment of Epilepsy, 2nd edn. Malden, MA: Blackwell Publishing, 2004: 500-506.
4. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol Rev 1990; 42: 223-286.
5. Bialer M, Johannessen S, Kupferberg H, Levy R, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT 8). Epilepsy Res 2007; 73: 1-52.
6. McLean JM, Schmutz M, Pozza M, Wamil AW. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Epilepsia 2005; 46: 296.
7. Payne-Parish J, Taylor J. The pharmacologic effect of rufinamide in vitro and in vivo. 36th Annual Meeting of the Society of Neuroscience, 14-18 October 2006, Atlanta, Georgia, USA.
8. Schmutz M, Allgeier H, Jeker A, et al. Anticonvulsant profile of CGP 33101in animals. Epilepsia 1993; 34: 122.
9. White HS, Schmutz M, Pozza M, Wolf H, Stables J, Kupferberg H. The anticonvulsant profile and tolerability of rufinamide in mice and rats. Epilepsia 2005; 46: 305-306.
10. Kupferberg HJ, Schmutz M. Screening of new compounds and the role of the pharmaceutical industry. In: Engel J, Pedley TA (eds). Epilepsy: A Comprehensive Textbook. Philadelphia, PA: Lippincott-Raven Publishers, 1997: 1417-34.
11. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49: 1123-1141.
12. Waldmeier F, Gschwind HP, Rouan MC, SioufiA, Czendlik C. Metabolism of the new anticonvulsive trial drug rufinamide (CGP 33101) in healthy male volunteers. Epilepsia 1996; 37(Suppl. 5): 167.
13. Kapeghian JC, Madan A, Parkinson A, Tripp SL, Probst A. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro. Epilepsia 1996; 37(Suppl. 5): 26.
14. Sachdeo RC, Rosenfeld WE, Choi L, Yeh CM, Cooper AN, Karolchyk MA. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy. Epilepsia 1998; 39(Suppl. 6):166-167.
15. Arroyo S, Sachdeo R, Rosenfeld W, Critchley D, Perdemo C. Pharmacokinetics and safety of ascending doses of adjunctive rufinamide in pediatric patients with inadequately controlled seizures. Epilepsia 2005; 46: 193.
16. Cheung WK, Kianifard F, Wong A, et al. Intra-and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res 1995; 12: 1878-1882.
17. Cardot JM, Lecaillon JB, Czendlik C, Godbillon J. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm Drug Dispos 1998; 19: 259-262.
18. Critchley D, Fuseau E, Perdomo C, Arroyo S. Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia 2005; 46: 209.
19. Chang SW, Choi L, Karolchyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia 1998; 39(Suppl. 6): 59.
20. Chang SW, Yeh CM, Van Logtenberg M, Sedek G, Karolchyk MA. A geriatric pharmacokinetic evaluation of rufinamide. Clin Pharmacokinet 1996; 31: 29-46.
21. Fuseau E, Critchley D, Perdomo C, Arroyo S. Population pharmacokinetics drug-drug interaction analysis of rufinamide studies in patients with epilepsy. Epilepsia 2005; 46: 210-211.
22. Elger C, Stefan H, Perdomo C, Arroyo S. Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures. Epilepsia 2005; 46: 83-84.
23. Perucca E, Cloyd J, Critchley D. The pharmacokinetics of the new antiepileptic drug rufinamide. 59th Annual American Epilepsy Society Meeting, 2-6 December 2005; Washington DC, USA.
24. Katenka D, Choi L, Chen BL, Karolchyk MA. Single center open label multiple dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Epilepsia 1998; 39: 59.
25. Rouan MC, Souppart C, Alif L, Meoes D, Lecaillon JB, Godbillon J. Automated analysis of a novel antiepileptic compound, CGP 33101, and its metabolite, CGP 47292, in body fluids by high-performance liquid chromatography and liquid-solid extraction. J Chromatog B Biomed Appl 1995; 667: 207-13.
26. Brunner LA, Powel ML. An automated method for the determination of new potential anti-epileptic agent (CGP 33101) in human plasma using high performance liquid chromatography. Biomed Chromatogr 1992; 6; 278-82.
27. Todorov A, Biton V, Krauss GL, Perdomo C, Arroyo S. Efficacy and safety of high-versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures. Epilepsia 2005; 46; 218-219.
28. Lesser R, Biton V, Sackellares JC, Van Ness P, Perdomo C, Arroyo S. Efficacy and safety of rufinamide monotherapy for the treatment of patients with refractory partial seizures. Epilepsia 2005; 46: 177-178.
29. Elger C, Stefan H, Perdomo C, Arroyo S. Dose-response relationships of rufinamide in patients with inadequately controlled partial seizures. Neurology 2006; 66(Suppl. 2); P01.102.
30. Palhagen S, Canger R, Henriksen O, van Parys JA, Riviere ME, Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res 2001; 43: 115-124.
31. Vasquez BR, Sachdeo R, Maxoutova AL, Beydoun A, Karolchyk MA, Mesenbrink PG. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy-resistant partial-onset seizures. Epilepsia 2000; 41: 255.
32. Rosenfeld W, Brodie MJ, Vazquez B, et al. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures. Epilepsia 2006; 47(Suppl. 3): 140.
33. Brodie M J, Rosenfeld W, Vasquez B, et al. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures. Epilepsia 2005; 47: 171.
34. Glauser T, Arzimanoglou A, Litzinger M, et al. Efficacy and safety of rufinamide as adjunctive therapy for inadequately controlled partial seizures in pediatric patients. Epilepsia 2005; 46: 194-195.
35. Biton V, Sachdeo R, Rosenfeld W, Schachter S, Perdomo C, Arroyo S. Efficacy and safety of adjunctive rufinamide in patients with inadequately controlled primary generalized tonic-clonic seizures. Epilepsia 2005; 46(8): 206.
36. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter randomized doubleblind placebo controlled parallel trial. 59th Ann Am Epilepsy Soc Meet, December 2-6, 2005; Washington, DC, USA.
37. Glauser T, Kluger G, Krauss G, Perdomo C, Arroyo S. Short term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia 2006; 47 (Suppl. 3): 139.
38. Glauser T, Kluger G, Krauss G, Perdomo C, Arroyo S. Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Neurology 2006; 66: 1-96.
39. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanics of action and place in therapy. Drugs 2000; 60: 1029-1052.
40. Aldenkamp A, Alpherts W. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 2006; 47: 1153-1159.
41. Krauss GL, Perdomo CA, Arroyo S. Short and long-term safety of rufinamide in patients with epilepsy. Epilepsia 2005; 46: 213.